Deborah I Friedman1, Michael P McDermott, Karl Kieburtz, Mark Kupersmith, Ann Stoutenburg, John L Keltner, Steven E Feldon, Eleanor Schron, James J Corbett, Michael Wall. 1. Departments of Neurology & Neurotherapeutics and Ophthalmology (DIF), University of Texas Southwestern Medical Center, Dallas, Texas; Departments of Ophthalmology, Neurology, Neurosurgery and Visual Science (SEF), Center for Human Experimental Therapeutics (KK, AS), Department of Biostatistics and Computational Biology and Department of Neurology (MM), University of Rochester School of Medicine and Dentistry, Rochester, New York; Neurology (MW), University of Iowa College of Medicine and Iowa City Veterans Affairs Health Care System, Iowa City, Iowa; National Eye Institute (ES), Bethesda, Maryland; Department of Ophthalmology and Vision Science (JK), University of California Davis Medical Center, Sacramento, California; Departments of Neurology and Ophthalmology (MK), Mount Sinai School of Medicine, New York, New York.
Abstract
BACKGROUND: The objectives of this study were to present the rationale for the main aspects of the study design and describe the trial methodology for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). METHODS:Eligible candidates with mild visual field loss (automated perimetric mean deviation [PMD] -2 to -7 dB) were randomized to receive either acetazolamide or matching placebo tablets. Randomized participants were offered participation in a supervised dietary program. The primary outcome variable, PMD, was measured at 6 months. Additionally, cerebrospinal fluid from subjects and serum from study participants and matched controls were collected for genetic analysis and vitamin A studies. An ancillary optical coherence substudy was added to investigate the changes of papilledema in the optic nerve head and retina that correlate with Frisén grading, visual field deficits, and low-contrast visual acuity. RESULTS: The randomized trial entered 165 participants from March 17, 2010, through November 27, 2012, from the United States and Canada. The primary outcome (month 6) visits were successfully completed by June 15, 2013. Blood specimens were obtained from 165 controls without IIH to investigate vitamin A metabolism and genetic markers of potential risk factors for IIH. CONCLUSIONS: The IIHTT is the first randomized, double-masked placebo-controlled trial to study the effectiveness of medical treatment for patients with IIH.
RCT Entities:
BACKGROUND: The objectives of this study were to present the rationale for the main aspects of the study design and describe the trial methodology for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). METHODS: Eligible candidates with mild visual field loss (automated perimetric mean deviation [PMD] -2 to -7 dB) were randomized to receive either acetazolamide or matching placebo tablets. Randomized participants were offered participation in a supervised dietary program. The primary outcome variable, PMD, was measured at 6 months. Additionally, cerebrospinal fluid from subjects and serum from study participants and matched controls were collected for genetic analysis and vitamin A studies. An ancillary optical coherence substudy was added to investigate the changes of papilledema in the optic nerve head and retina that correlate with Frisén grading, visual field deficits, and low-contrast visual acuity. RESULTS: The randomized trial entered 165 participants from March 17, 2010, through November 27, 2012, from the United States and Canada. The primary outcome (month 6) visits were successfully completed by June 15, 2013. Blood specimens were obtained from 165 controls without IIH to investigate vitamin A metabolism and genetic markers of potential risk factors for IIH. CONCLUSIONS: The IIHTT is the first randomized, double-masked placebo-controlled trial to study the effectiveness of medical treatment for patients with IIH.
Authors: Mark J Kupersmith; Patrick A Sibony; Steven E Feldon; Jui-Kai Wang; Mona Garvin; Randy Kardon Journal: Am J Ophthalmol Date: 2016-12-28 Impact factor: 5.258
Authors: Jorge C Kattah; John H Pula; Luis J Mejico; Michael P McDermott; Mark J Kupersmith; Michael Wall Journal: J Neurol Date: 2015-07-10 Impact factor: 4.849
Authors: Michael Wall; Michael P McDermott; Karl D Kieburtz; James J Corbett; Steven E Feldon; Deborah I Friedman; David M Katz; John L Keltner; Eleanor B Schron; Mark J Kupersmith Journal: JAMA Date: 2014 Apr 23-30 Impact factor: 56.272
Authors: Michael Wall; Mark J Kupersmith; Karl D Kieburtz; James J Corbett; Steven E Feldon; Deborah I Friedman; David M Katz; John L Keltner; Eleanor B Schron; Michael P McDermott Journal: JAMA Neurol Date: 2014-06 Impact factor: 18.302
Authors: Peggy Auinger; Mary Durbin; Steven Feldon; Mona Garvin; Randy Kardon; John Keltner; Mark Kupersmith; Patrick Sibony; Kim Plumb; Jui-Kai Wang; John S Werner Journal: Invest Ophthalmol Vis Sci Date: 2014-11-04 Impact factor: 4.799
Authors: J Libien; M J Kupersmith; W Blaner; M P McDermott; S Gao; Y Liu; J Corbett; M Wall Journal: J Neurol Sci Date: 2016-11-10 Impact factor: 3.181
Authors: Kathleen B Digre; Beau B Bruce; Michael P McDermott; Kristin M Galetta; Laura J Balcer; Michael Wall Journal: Neurology Date: 2015-05-20 Impact factor: 9.910
Authors: Deborah I Friedman; Peter A Quiros; Prem S Subramanian; Luis J Mejico; Shan Gao; Michael McDermott; Michael Wall Journal: Headache Date: 2017-07-28 Impact factor: 5.887